GSA. The Federal Center was acquired in 1941 by the U.S. government and is currently used for office, research, and administrative purposes by 26 federal agencies. There are approximately 4 million square feet of space in approximately 50 active buildings at the Federal Center, and there are approximately 6,000 on-site employees. The site, formerly part of unincorporated Jefferson County, Colorado, was recently annexed into the City of Lakewood. Annexation has no affect on the federal ownership or management of the site. GSA recently sold 65 of the facility the City of Lakewood through the federal land disposal process for construction of an inter-modal transit station and relocation of St. Anthony Hospital. GSA proposes to implement a new Master Site Plan for the Federal Center that will address new opportunities for site development. The FEIS, prepared to comply with the National Environmental Policy Act (NEPA), evaluates the proposed Master Site Plan alternatives and identifies the environmental effects associated with implementing the proposed alternatives. The Draft Master Site Plan and draft Environmental Impact Statement released in April 2007, evaluated two action alternatives, the Federal Quad Alternative and the Federal Mall Alternative; and a No Action Alternative. Under the No Action Alternative, GSA would not implement a new Master Site Plan for the Federal Center. Though currently planned upgrades to site infrastructure would move forward contingent upon funding, existing resources would not be leveraged to attract capital to the site, a new vision for growth would not be established, and the value and appeal of the Federal Center site would not be maximized. Under the No Action alternative, it would become increasingly difficult to maintain the resources on the site to serve Federal tenants and overall community needs. During the public review and comment period conducted between May and June 2007, over 300 hundred individual comments were received from 198 tenants, neighbors, groups, city, state, and federal offices. The Federal Quad concept, with modifications, is identified in the Final Master Site Plan and as the preferred alternative named in the FEIS. The defining characteristic of the Federal Quad Alternative is the central ''Quad'' that would be located in the center of the Federal Center site. The enhanced streetscapes throughout the campus would encourage area employees and residents to walk to and from transit and into adjacent districts. The Quad would be the heart of the plan and would be woven into the fabric of the surrounding neighborhoods and commercial districts via road and land use connections. The Quad would be surrounded by complementary office buildings, including secure federal buildings, non-secure federal buildings, and research buildings. A total of 227 acres (or approximately 36 percent of the total site) would be designated for open space use. The Federal Quad Alternative includes a development plan with approximately 3.6 million gross square feet of new development, plus 1,400 residential units, organized around a formal open space/park area that suggests a university campus setting. The primary change in this alternative between the Draft Master Site Plan and the Final is additional residential units in the northwest area of the site in the vicinity of the anticipated transit-orientated development and intermodal station. The modified Federal Quad Alternative as presented in the Final Master Site Plan for the Federal Center reflects GSA's preferred development strategy.

Dated: January 24, 2008.

Steven M. Burke,

Acting Director, General Services Administration, DFC Service Center, PBS, Rocky Mountain Region.

[FR Doc. E8–1908 Filed 1–31–08; 8:45 am]

BILLING CODE 6820–BK–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Medicare & Medicaid Services

[Document Identifier: CMS–R–50]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Centers for Medicare & Medicaid Services, HHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Centers for Medicare & Medicaid Services (CMS) is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* Extension of a currently approved collection; *Title of Information Collection:* Medical Records Review under the Prospective Payment System (PPS) and Supporting Regulations in 42 CFR 412.40–412.52 *Use:* The Social Security Amendments of 1983 (Pub. L. 98–21), requires quality improvement organization (QIO) review of medical services provided to Medicare beneficiaries. Review of services under the QIO program can be accomplished by individual case review and the Clinical Data Abstraction Centers (CDACs). Accordingly, QIOs must review, at the direction of CMS: (1) All anti-dumping referrals; (2) beneficiary complaints involving quality issues; (3) potential gross and flagrant violations of unnecessary admission concerns identified during project data collection; (4) requests from hospitals for higher-weighted DRG adjustments; (5) hospital and managed care plan issued notices of non-coverage; (6) specific codes for assistants at cataract surgery; and (7) cases referred by CMS, the Office of the Inspector General, the Department of Justice, the managed care appeals contractor, intermediaries, carriers, or the CDACs. *Form Number:* CMS–R–50 (OMB# 0938–0359); *Frequency:* Yearly; *Affected Public:* Private sector—Business or other for-profit and Not-for-profit institutions; *Number of Respondents:* 6,100; *Total Annual Responses:* 276,500; *Total Annual Hours:* 8,280.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, access CMS' Web site address at *http://www.cms.hhs.gov/PaperworkReductionActof1995,* or e-mail your request, including your address, phone number, OMB number, and CMS document identifier, to *Paperwork@cms.hhs.gov,* or call the Reports Clearance Office on (410) 786–1326.

In commenting on the proposed information collections, please reference the document identifier or OMB control number. To be assured consideration, comments and recommendations must be submitted in one of the following ways by April 1, 2008:

1. *Electronically.* You may submit your comments electronically to *http://www.regulations.gov.* Follow the instructions for ''Comment or

Submission'' or ''More Search Options'' to find the information collection document(s) accepting comments.

2. *By regular mail.* You may mail written comments to the following address: CMS, Office of Strategic Operations and Regulatory Affairs, Division of Regulations Development, *Attention:* Document Identifier/OMB Control Number _____, Room C4–26–05, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: January 25, 2008.

Michelle Shortt,

Director, Regulations Development Group, Office of Strategic Operations and Regulatory Affairs.

[FR Doc. E8–1810 Filed 1–31–08; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

President's Committee for People With Intellectual Disabilities; Notice of Quarterly Meeting

AGENCY: President's Committee for People with Intellectual Disabilities (PCPID); Administration for Children and Families; Department of Health and Human Services.

ACTION: Notice of Quarterly Meeting.

DATES: February 15, 2008, from 3:30 p.m. to 5:30 p.m. EST. The meeting will be conducted via conference call and will be open to the public using the dial-in information provided below.

ADDRESSES: The conference call may be accessed on the date and time indicated by dialing 888–677–5720, passcode: 1397797.

Agenda: PCPID will meet to finalize the 2007 Report to the President and to hear a briefing on the final report of the Ticket to Work and Work Incentives Advisory Panel.

FOR FURTHER INFORMATION CONTACT: Sally D. Atwater, Executive Director, President's Committee for People with Intellectual Disabilities, The Aerospace Center, Second Floor, West, 370 L'Enfant Promenade, SW., Washington, DC 20447. Telephone: 202–619–0634, Fax: 202–205–9591. E-mail: *satwater@acf.hhs.gov.*

SUPPLEMENTARY INFORMATION: PCPID acts in an advisory capacity to the President and the Secretary of Health and Human Services on a broad range of topics relating to programs, services and supports for persons with intellectual disabilities. PCPID, by Executive Order, is responsible for evaluating the adequacy of current practices in programs, services and supports for persons with intellectual disabilities, and for reviewing legislative proposals that impact the quality of life experienced by citizens with intellectual disabilities and their families.

Dated: January 25, 2008.

Sally D. Atwater,

Executive Director, President's Committee for People with Intellectual Disabilities.

[FR Doc. E8–1809 Filed 1–31–08; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Notification from Industry Organizations Interested in Participating in the Selection Process for a Nonvoting Industry Representative on the Blood Products Advisory Committee and Request for Nominations for a Nonvoting Industry Representative on the Blood Products Advisory Committee

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting that any industry organizations interested in participating in the selection of a nonvoting industry representative to serve on the Blood Products Advisory Committee, Center for Biologics Evaluation and Research (CBER), notify FDA in writing. A nominee may either be self-nominated or nominated by an organization to serve as a nonvoting industry representative. Nominations will be accepted for an upcoming vacancy on September 30, 2008, effective with this notice.

DATES: Any industry organization interested in participating in the selection of an appropriate nonvoting member to represent industry interests must send a letter stating the interest to FDA by March 3, 2008, for vacancies listed in the notice. Concurrently, nomination material for prospective candidates should be sent to FDA by March 3, 2008.

ADDRESSES: All letters of interest and nominations should be submitted in writing to Donald W. Jehn (see **FOR FURTHER INFORMATION CONTACT**).

FOR FURTHER INFORMATION CONTACT: Donald W. Jehn, Division of Scientific Advisors and Consultants, Center for Biologics Evaluation and Research, Food and Drug Administration (HFM–71), 1401 Rockville Pike, Rockville, MD 20892, 301–827–1277, *donald.jehn@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: The agency requests nominations for a nonvoting industry representative to the Blood Products Advisory Committee.

I. Function

The Blood Products Advisory Committee reviews and evaluates available data concerning the safety, effectiveness, and appropriate use of blood products derived from blood and serum or biotechnology which are intended for the use in the diagnosis, prevention, or treatment of human diseases, and, as required, any other product for which FDA has regulatory responsibility. The committee also advises the Commissioner of Food and Drugs (the Commissioner) on its findings regarding the safety, effectiveness, and labeling of the products, clinical and laboratory studies involving such products, the affirmation or revocation of biological product licenses, and on the quality and relevance of FDA's research program which provides the scientific support for regulating these agents.

II. Selection Procedure

Any blood products industry, association, or organization interested in the selection of an appropriate nonvoting member to represent industry interests should send a letter stating that interest to the FDA contact (see **FOR FURTHER INFORMATION CONTACT**) within 30 days of publication of this document (see **DATES**). Within the subsequent 30 days, FDA will send a letter to each organization that has expressed an interest, attaching a complete list of all such organizations and a list of all nominees along with their current resumes. The letter will also state that it is the responsibility of the interested organizations to confer with one another and to select a primary and alternate candidate, within 60 days after the receipt of the FDA letter, and the primary candidate will serve as the nonvoting member to represent industry interests for the Blood Products Advisory Committee. The interested organizations are not bound by the list of nominees in selecting a candidate. However, if no individual is selected within 60 days, the Commissioner will select the nonvoting member to represent industry interests.

III. Application Procedure

Individuals may self nominate and/or an organization may nominate one or more individuals to serve as a nonvoting